Karin Hellsvik joined Foghorn Therapeutics in 2022 as vice president, corporate affairs. She brings 20 years of skill and passion for improving patient care with extensive experience in communications, advocacy and thought leadership in complex disease areas, from early-stage development to commercialization.
She most recently headed corporate affairs for Biogen’s Alzheimer’s Business unit where she led a global team overseeing communications, patient advocacy and social and digital communications. Prior to Biogen’s Alzheimer’s program, she spent 4 years at the company’s international headquarters in Switzerland forming the Patient Advocacy function and strategy in Europe for Biogen’s disease areas (MS and Rare Disease /SMA, ALS). She also served as Biogen’s Head of Patient Communications in the Nordic region, based in Copenhagen.
Prior to Biogen, Karin spent almost 10 years advising a broad range of clients on pharmaceutical communications and advocacy at leading Nordic healthcare communications agencies. She has an educational background in communications and marketing from Sweden and added to her understanding of global healthcare and disparities at MGH Disparities Leadership Program at Mongan Institute Health Policy Research Center, MGH, Boston.